| Income Statement | 2025-09-30 | 2025-07-31 | 2024-10-31 | |
|---|---|---|---|---|
| Product revenue, net | 13,692 | 1,426 | - | |
| General and administrative expense, total | - | - | 29,201 | |
| Cost of revenue | 1,232 | 590 | - | |
| Research and development | 11,993 | 15,162 | 16,610 | |
| Selling, general and administrative | 46,517 | 44,683 | - | |
| Total operating expenses | 59,742 | 60,435 | 45,811 | |
| Operating loss | -46,050 | -59,009 | -45,811 | |
| Interest income | 1,875 | 1,849 | 1,357 | |
| Interest expense | 4,757 | 3,522 | - | |
| Foreign currency exchange (loss) gain | -884 | 1,925 | 67 | |
| Other income, net | 2,491 | 818 | 2,119 | |
| Total other (expense) income | -1,275 | 1,070 | 3,543 | |
| Loss before income tax expense | -47,325 | -57,939 | - | |
| Income tax expense | 2,157 | 2,157 | - | |
| Net loss | -49,482 | -60,096 | -42,268 | |
| Foreign currency translation gain (loss) | 911 | -604 | 166 | |
| Unrealized holding gain on marketable securities | 187 | 18 | 651 | |
| Reclassification adjustment for realized holding gain on marketable securities included in net loss | 771 | 587 | 649 | |
| Total other comprehensive (loss) income | 327 | -1,173 | 168 | |
| Comprehensive loss | -49,155 | -61,269 | -42,100 | |
| Earnings per share, basic | -0.92 | -1.12 | -0.91 | |
| Earnings per share, diluted | -0.92 | -1.12 | -0.91 | |
| Weighted average number of shares outstanding, basic | 53,883,681 | 53,497,128 | 46,695,220 | |
| Weighted average number of shares outstanding, diluted | 53,883,681 | 53,497,128 | 46,695,220 | |
KalVista Pharmaceuticals, Inc. (KALV)
KalVista Pharmaceuticals, Inc. (KALV)